- Home
- PRFX vs RDHL Comparison
PRFX vs RDHL Comparison
Compare PRFX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- RDHL
- Stock Information
- Founded
- PRFX 2007
- RDHL 2009
- Country
- PRFX Israel
- RDHL Israel
- Employees
- PRFX N/A
- RDHL N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- RDHL Health Care
- Exchange
- PRFX Nasdaq
- RDHL Nasdaq
- Market Cap
- PRFX 3.3M
- RDHL 3.9M
- IPO Year
- PRFX 2020
- RDHL N/A
- Fundamental
- Price
- PRFX $1.63
- RDHL $1.23
- Analyst Decision
- PRFX Hold
- RDHL
- Analyst Count
- PRFX 1
- RDHL 0
- Target Price
- PRFX N/A
- RDHL N/A
- AVG Volume (30 Days)
- PRFX 8.7M
- RDHL 92.1K
- Earning Date
- PRFX 09-16-2025
- RDHL 09-05-2025
- Dividend Yield
- PRFX N/A
- RDHL N/A
- EPS Growth
- PRFX N/A
- RDHL N/A
- EPS
- PRFX N/A
- RDHL N/A
- Revenue
- PRFX N/A
- RDHL $8,042,999.00
- Revenue This Year
- PRFX N/A
- RDHL $381.91
- Revenue Next Year
- PRFX N/A
- RDHL N/A
- P/E Ratio
- PRFX N/A
- RDHL N/A
- Revenue Growth
- PRFX N/A
- RDHL 23.17
- 52 Week Low
- PRFX $1.25
- RDHL $1.06
- 52 Week High
- PRFX $16.63
- RDHL $12.50
- Technical
- Relative Strength Index (RSI)
- PRFX 53.13
- RDHL 37.81
- Support Level
- PRFX $1.34
- RDHL $1.28
- Resistance Level
- PRFX $1.92
- RDHL $1.40
- Average True Range (ATR)
- PRFX 0.27
- RDHL 0.07
- MACD
- PRFX -0.02
- RDHL 0.01
- Stochastic Oscillator
- PRFX 13.05
- RDHL 3.85
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.